GLP-1 Pill Cuts Weight 12%; U.S. Measles Sets 35-Year Record; Brain Immunity Shifts at 50
Oral aleniglipron achieves 12% weight loss; U.S. measles hits a 35-year high; a wearable REM patch; brain immunity rewires at midlife.
By Dr. Asher Knippel
This week in health: an oral GLP-1 drug posts phase 2 data that rival injectables; the United States measles case count reaches levels not seen since 1991; a wearable ultrasound patch accelerates entry into restorative sleep without medication; and new research finds that the brain's immune landscape undergoes a profound, previously unrecognised shift beginning around age 50.
June–August 2026: Oral GLP-1 Drug Aleniglipron Achieves 12% Weight Loss in Phase 2b Trial
The promise of a once-daily GLP-1 pill has long been overshadowed by the superior efficacy of injectable analogues. Aleniglipron, a small-molecule GLP-1 receptor agonist developed by Structure Therapeutics, may narrow that gap. In a randomised, double-blind, placebo-controlled phase 2b trial published in Nature Medicine, 230 adults with obesity or overweight were assigned to once-daily oral aleniglipron at 45, 90, or 120 mg, or placebo, for 36 weeks.
Mean body-weight reductions were 9.0%, 10.7%, and 12.1% at the three doses, respectively, compared with 0.5% with placebo — results that compare favourably with the approximately 15% loss seen with injectable semaglutide (Wegovy) in similarly structured trials. A key practical advantage: unlike oral semaglutide (Rybelsus), which must be taken fasting and 30 minutes before eating, aleniglipron can be taken with or without food, potentially improving real-world adherence. Gastrointestinal adverse events — nausea, vomiting, diarrhoea — were mostly mild to moderate and declined over time; the discontinuation rate was 10.4%, and no cases of drug-induced liver injury were observed. Structure Therapeutics plans to advance aleniglipron into phase 3 evaluation, supported by extended 44-week follow-up data showing placebo-adjusted weight loss of up to 16.3% at 180 mg.
August 2026: U.S. Measles Cases Hit a 35-Year High, Threatening Elimination Status
The United States has recorded 2,465 confirmed measles cases in 2026 — the highest annual total since 1991 and the second consecutive record-breaking year. Cases span 47 jurisdictions, with the largest clusters in South Carolina (670 cases), Utah (490), Texas (182), and Florida (141). Some 2,309 of those 2,465 cases (94%) are outbreak-associated, spread across 38 distinct outbreaks.
The resurgence is driven primarily by declining childhood vaccination rates: the CDC reports that 93% of infected individuals were unvaccinated. Measles was declared eliminated from the United States in 2000, a status requiring the interruption of endemic transmission. That status is now under formal review — authorities plan to re-examine whether the U.S. still meets elimination criteria in November 2026. Two doses of the measles-mumps-rubella (MMR) vaccine are approximately 97% effective; the CDC recommends children receive the first dose at 12–15 months and the second at 4–6 years.
August 2026: Wearable Ultrasound Patch Gets Sleepers into REM 43 Minutes Faster
Researchers at the University of Texas at Austin have developed NEUSLeeP, a soft wearable patch that combines gentle low-intensity focused ultrasound stimulation with real-time electroencephalography (EEG) monitoring. In a pilot study of 28 participants, the device shortened the time to REM sleep by 43 minutes and extended total time in REM by approximately 16 minutes — without medication or surgical intervention.
The patch's real-time feedback loop is central to how it works: EEG electrodes continuously track neural activity, and the ultrasound component modulates deep brain structures involved in sleep regulation. Beyond sleep architecture, researchers observed signs of improved stress regulation and changes in brain circuits associated with emotional processing. NEUSLeeP could eventually benefit people with post-traumatic stress disorder, major depression, and chronic insomnia — conditions in which disrupted REM sleep plays a well-documented role. The team has announced plans for larger confirmatory studies; the current findings remain preliminary and are awaiting peer review.
August 2026: The Brain's Hippocampal Immune Cells Quietly Rebuild — and Inflame — Starting at 50
The hippocampus, the brain's primary hub for learning and memory, undergoes a previously unrecognised immune overhaul beginning in midlife, according to a study published in Science and funded by the National Institutes of Health. Using single-cell sequencing to examine gene regulation and three-dimensional genome architecture in individual hippocampal cells from human donors, researchers found that the brain's resident immune cells — microglia — progressively decline between approximately ages 50 and 75 and are replaced by cells bearing elevated inflammatory signatures, with molecular features resembling peripheral blood-derived immune cells.
The implications for Alzheimer's disease research are significant. Chronic neuroinflammation is a well-established feature of Alzheimer's pathology, and a cellular transition beginning around age 50 would precede the typical onset of clinical symptoms by roughly two decades — closely matching the long preclinical period identified by amyloid and tau biomarker studies. The authors describe their paper, "Epigenetic and 3D genome reprogramming during the aging of human hippocampus" (DOI: 10.1126/science.adt8307), as opening a new window on why aging is the single greatest risk factor for Alzheimer's and related dementias. Whether this inflammatory shift can be delayed, reversed, or therapeutically targeted remains an open question.
This article is a journalistic summary of health and medicine developments and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health routines.